- ISIN
- US60855D2009
- CUSIP
- 60855D200
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 2, 2016
Highlights
- Market Cap
- $2.13M
- Enterprise Value
- -$8.00M
- EPS (TTM)
- -$1.67
- Gross Profit (TTM)
- -$59.00K
- EBITDA (TTM)
- -$26.97M
- Year Range
- $0.31 - $18.25
- ROA (TTM)
- -129.83%
- ROE (TTM)
- -199.78%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $837.11K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MBRX Performance Chart
Moleculin Biotech, Inc. (MBRX) is down 87.9% since the beginning of the year. At $0 per share, MBRX is trading 97.8% below its 52-week high of $18. Investors who bought $1,000 worth of MBRX shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Moleculin Biotech, Inc. (MBRX) has returned -87.92% so far this year and -97.59% over the past 12 months. Over the last ten years, MBRX has returned -65.24% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Moleculin Biotech, Inc.
- 1D
- -60.78%
- 1M
- -84.85%
- 6M
- -90.68%
- YTD
- -87.92%
- 1Y
- -97.59%
- 3Y*
- -88.26%
- 5Y*
- -79.73%
- 10Y*
- -65.24%
- ALL TIME*
- -65.56%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MBRX Monthly Returns History
Based on dividend-adjusted daily data since Jun 2, 2016, MBRX's average daily return is -0.11%, while the average monthly return is -4.36%.
Historically, 30% of months were positive and 70% were negative. The best month was Jun 2017 with a return of +146.2%, while the worst month was Jul 2026 at -85.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 9 months.
On a daily basis, MBRX closed higher 41% of trading days. The best single day was Feb 13, 2025 with a return of +202.4%, while the worst single day was Jul 31, 2026 at -60.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 29.61% | -44.29% | -4.18% | 11.79% | 8.98% | -0.00% | -85.66% | -87.92% | |||||
| 2025 | -11.18% | -14.57% | -24.53% | 8.87% | -17.92% | -65.30% | 108.02% | -37.52% | 35.07% | -12.19% | -41.41% | -51.45% | -92.21% |
| 2024 | -41.29% | 24.80% | -37.36% | -15.06% | -4.98% | -26.21% | -10.51% | -19.05% | 11.37% | -8.45% | 6.54% | -38.63% | -86.80% |
| 2023 | 18.86% | -3.96% | -20.66% | -22.16% | -15.23% | -8.63% | 9.40% | -11.56% | -23.66% | 11.13% | 26.02% | 43.38% | -19.02% |
| 2022 | -18.82% | -7.95% | 28.06% | -10.67% | -5.66% | -3.33% | 16.55% | -12.43% | -28.38% | -5.66% | 44.00% | -26.39% | -43.01% |
| 2021 | 3.94% | -14.91% | -3.55% | -13.97% | 5.41% | -0.81% | -14.99% | -1.28% | -2.60% | -12.00% | -21.59% | -10.14% | -61.11% |
Benchmark Metrics
Moleculin Biotech, Inc. has an annualized alpha of -34.29%, beta of 0.94, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 02, 2016.
- This stock participated in 255.87% of S&P 500 Index downside but only -55.14% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -34.29%
- Beta
- 0.94
- R²
- 0.01
- Upside Capture
- -55.14%
- Downside Capture
- 255.87%
Return for Risk
Risk / Return Rank
MBRX ranks 4 for risk / return — above 4% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Moleculin Biotech, Inc. (MBRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MBRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.18 | ||
| Sortino ratioReturn per unit of downside risk | -4.21 | ||
| Omega ratioGain probability vs. loss probability | 0.64 | 1.25 | -0.61 |
| Calmar ratioReturn relative to maximum drawdown | -1.00 | 2.00 | -3.00 |
| Martin ratioReturn relative to average drawdown | -1.40 | 8.49 | -9.89 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Moleculin Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Moleculin Biotech, Inc. was 100.00%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current Moleculin Biotech, Inc. drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Jul 2026 | 10y 2mo | — | 10y 2moJun 2016 - now | — |
Drawdown Indicators
| MBRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -97.67% | -9.10% | -88.57% |
Max Drawdown (3Y)Largest decline over 3 years | -99.89% | -18.90% | -80.99% |
Max Drawdown (5Y)Largest decline over 5 years | -99.97% | -25.43% | -74.54% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -89.69% | -10.70% | -78.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 69.51% | 2.14% | +67.37% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Moleculin Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Moleculin Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MBRX in comparison with other companies in the Biotechnology industry. Currently, MBRX has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MBRX
Add Moleculin Biotech, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MBRX